Planned Parenthood plans to withdraw from Title X program, amid looming Trump Administration rule changes; a new cure accepted by the FDA for a deadly strain of tuberculosis has been found to have a 90% success rate in a patient trial; opioid distribution to patients has began to change amongst doctors with new recommendations based around set prescribing levels.
Planned Parenthood announced Wednesday it will soon leave Title X, the federal family planning program, barring a court decision to delay Trump administration rules that bar clinics from referring patients for abortions, Associated Press reported. HHS stated the agency's willingness to accommodate clinics that are making efforts to comply with upcoming rule changes, but Planned Parenthood's spokeswoman Erica Sackin stated the organization’s intent to leave the program, due to regulations set to take effect September 18.A small trial consisting of 109 patients has shown a groundbreaking success rate of 90% against a deadly strain of drug-resistant tuberculosis. This particular XDR strain is involved in about 30,000 cases in over 100 countries, with a cure rate of only 34%. The New York Times reported that the FDA has endorsed the new approach by approving the use of 3 pills: pretomanid, bedaquiline, and linezolid. The treatment can soon come into use worldwide. Narcotic prescriptions have been reduced by nearly one-third since October 2017, after growing concern about the opioid crisis, Kaiser Health News reports. Surgeons stated the transition of narcotic prescriptions have changed dramatically since the beginning of their careers as there was little or no information recommended to them about pill distribution to patients after procedures. The Michigan OPEN guidelines now recommends for no more than 10 pills, equivalent to 5 mg of oxycodone, for an operation such as a minor hernia repair, as opposed to the 29 pills prescribed in the past.
Urticaria Diagnosis Challenged by Overlapping Pruritic Skin Conditions
April 23rd 2025Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification in literature of distinct pathologies like vasculitic urticaria and bullous pemphigus.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More